The fusion protein is composed of a CD30 binding domain (HRS3-scFv) that is linked via the human IgG hinge-CH2/CH3 domain to human IL12. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD30 as well as the biological activity of IL12. The antibody-cytokine fusion proteins enhanced the cytolysis of CD30+ tumor cells and IFN-γ secretion by NK cells, and increased the activation of resting NK cells. These results support the concept that the HRS3-scFv-Fc-(IL12) fusion protein could be valuable for the specific immunotherapy of Hodgkin's lymphoma. This immunocytokine was designed for treating Hodgkin's disease (HD) anaplastic large cell lymphoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-144 | Anti-Human CD30 Recombinant Antibody (Iratumumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
There are currently no Customer reviews or questions for ACFP-SH124. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.